knowledge -WSS

knowledge

author：knowledge 2025-09-27 22:45:56 - browse：548

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Juul documents reveal insider tactics on political lobbying

entertainment

hotspot

WSS

ACIP vaccine advisory panel sees its vacancies filled

In the gardens at Boston Children's Hospital, families find sanctuary

Search called off for baby washed away in Pennsylvania flash flood

Why Eli Lilly’s earnings didn’t quite live up to the hype

Websites selling Wegovy, Zepbound ingredients targeted by FDA

What causes rare myocarditis in young men after Covid vaccines?

leisure time

knowledge

Wikipedia

Medical records are filled with copy

ACIP vaccine advisory panel sees its vacancies filled

Affirmative action in medical school literally saved lives

Dems pitch expanding Medicare power to negotiate drug prices

Wildfire smoke exposes gaps in outdoor worker protections

Study gives hint on South Asians’ higher risk of cardiovascular disease

Medical records are filled with copy

AMAs digital advisors table RPM coding reform proposal, again

Apple is now the first public company to be valued at $3 trillion

Study gives hint on South Asians’ higher risk of cardiovascular disease

focus

What to watch for from Zogenix and Amicus clinical trials

Artificial intelligence use in health care faces greater scrutiny in 2024

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Latigo launches with $135 million for Vertex

A new crop of companies is reshaping the health data economy

Former reverend arrested for allegedly killing 8

entertainment

explore

hotspot

focus